Followers | 8 |
Posts | 1631 |
Boards Moderated | 0 |
Alias Born | 12/09/2000 |
Thursday, November 03, 2005 5:39:24 AM
11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.
Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.
The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.
http://realtimetraders.com/sp/breakingnews.asp?vid=9625264
ENTOURAGE MINING IHUB BOARD, DONT MISS IT. GOTTA BE IN IT TO WIN IT! GOT CMKX?
http://investorshub.advfn.com/boards/board.asp?board_id=4518
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM